Lesley Rhodes on Muck Rack

Lesley Rhodes

Dyersburg
As seen in: Wiley Online Library, Oxford Academic, PLOS ONE, ScienceDirect, Archives of Disease in Childhood, MDPI, Dialnet - Universidad de La Rioja

Get in touch with Lesley

Contact Lesley, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Lesley Rhodes’s Biography

Read Full Bio →

Buy Lopimune medicine reduces the amount of HIV in your blood and increases the number of T cells. Reducing the amount of HIV in the blood reduces the chance of death or infections that happen when your immune system is weak (opportunistic infections). Some of these conditions are pneumonia, herpes virus infections, and Mycobacterium Avium Complex (MAC) infections.!! https://www.alldaygeneric.com/product/lopimune-tablets/

Articles

Correction: Risk of ciguatoxins is shaped by Gambierdiscus community structure

|
By Kirsty Smith, Lesley Rhodes, Belinda Curley
| PLOS ONE
There are errors in the author affiliations. The correct affiliations are as follows: Kirsty F. Smith1, Lesley L. Rhodes1, Belinda Curley2, Arjun Verma3, Gurjeet Kohli3, D. Tim Harwood1, J. Sam Murray1, Jérôme Viallon4, Hélène Taiana Darius4, Mireille Chinain4, Teina Rongo5, June Hosking6, Phoebe A. Argyle1, Jacqui Stuart1, Shauna A.
Open in Who Shared Issue with article?

Risk of ciguatoxins is shaped by Gambierdiscus community structure

|
By Kirsty Smith, Lesley Rhodes, Belinda Curley
| PLOS ONE
Loading metrics Open Access Peer-reviewed Research Article Citation: Smith KF, Rhodes LL, Curley B, Verma A, Kohli G, Harwood DT, et al. (2026) Risk of ciguatoxins is shaped by Gambierdiscus community structure. PLoS One 21(1): e0341899. https://doi.org/10.1371/journal.pone.0341899 Editor: Elena Gorokhova, Stockholm University, SWEDEN Received: September 16, 2025; Accepted: January 14, 2026; Published: January 29, 2026 Copyright: © 2026 Smith et al.
Open in Who Shared Issue with article?

Volume 191 Issue 3

|
By Cathryn Sibbald, Coco Dekkers, Lesley Rhodes, Catherine M Olsen
| Oxford Academic Verified
Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study Mycosis fungoides (MF) and Sézary syndrome (SS) are chronic malignant diseases that require diverse strategies to achieve remission. Systemic interferon (IFN)-α has been used to treat MF/SS since 1984; however, its production was recently stopped.
Open in Who Shared Issue with article?
See all 10 licensed articles (12 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified